Dec 2
Proxy statement
DEFA14A
Proxy statement
HEPA · Hepion Pharmaceuticals, Inc. · Documents
$0.14
-0.18 (-57.55%)
At close · May 13
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern within one year of the issuance of these condensed consolidated financial statements without additional capital becoming available to us.”View the 10-Q filed Aug 13, 2026
Market Cap
$6.77M
Shares
90.22M
Volume · May 13
1.91M
Avg daily vol (40 sessions)
7.18M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2024
Nov 21
Current report
8-K
Events of Nov 20
Delisting notice or listing transfer
Nov 14
Quarterly report
10-Q
FY2024 Q3, ended Sep 30
Quarterly report for FY2024 Q3
Net loss $4.87M
Diluted EPS -$0.72
Sep 5
Current report
8-K
Events of Sep 3
Delisting notice or listing transfer
Aug 13
Quarterly report
10-Q
FY2024 Q2, ended Jun 30
Quarterly report for FY2024 Q2
Net loss $3.93M
Diluted EPS -$0.68
Aug 7
Current report
8-K
Events of Aug 5
Director or officer change, or executive pay
Jul 22
Jul 11
Registration statement
S-1
Registration statement
Jun 25
Annual report
10-K/A
Ended Dec 31
Annual report for the period ended Dec 31, 2023
May 21
Quarterly report
10-Q
FY2024 Q1, ended Mar 31
Quarterly report for FY2024 Q1
Revenue $0
Net loss $2.85M
Diluted EPS -$0.56
May 15
Late filing notice
NT 10-Q
Late filing notice
Apr 16
Annual report
10-K
FY2023, ended Dec 31
Annual report for FY2023
Revenue $0
Net loss $48.93M
Diluted EPS -$12.32
Apr 1
Late filing notice
NT 10-K
Late filing notice
Mar 6
Current report
8-K
Events of Mar 5
Director or officer change, or executive pay
Feb 20
Current report
8-K
Director or officer change, or executive pay
Feb 16
Current report
8-K
Events of Feb 15
Entered into a material agreement, Unregistered sale of equity
Feb 7
Current report
8-K
Director or officer change, or executive pay
Jan 3
Current report
8-K
Events of Dec 27
Change of auditor
2023
Dec 7
Current report
8-K
Events of Dec 4
Director or officer change, or executive pay, Other events
Nov 20
Quarterly report
10-Q
FY2023 Q3, ended Sep 30
Quarterly report for FY2023 Q3
Revenue $0
Net loss $10.53M
Diluted EPS -$2.74
Nov 14
Late filing notice
NT 10-Q
Late filing notice
Oct 31
Registration statement
S-1
Registration statement
Oct 3
Current report
8-K
Events of Sep 28
Entered into a material agreement, Unregistered sale of equity, Other events
Sep 6
Current report
8-K
Events of Aug 30
Director or officer change, or executive pay
Aug 14
Quarterly report
10-Q
FY2023 Q2, ended Jun 30
Quarterly report for FY2023 Q2
Revenue $0
Net loss $14.08M
Diluted EPS -$3.68
Jul 24
Current report
8-K
Regulation FD disclosure
Jul 21
Current report
8-K
Entered into a material agreement
Jun 22
Current report
8-K
Shareholder vote results
May 22
Current report
8-K
Regulation FD disclosure, Other events
May 12
Quarterly report
10-Q
FY2023 Q1, ended Mar 31
Quarterly report for FY2023 Q1
Revenue $0
Net loss $13.26M
Diluted EPS -$3.48
May 10
Current report
8-K
Charter or bylaw amendment, or fiscal year change, Other events
Apr 28
Proxy statement
DEF 14A
Meeting Jun 22, 2023
Proxy statement
Apr 28
Annual report to holders
ARS
Annual report to holders
Apr 28
Proxy statement
DEFA14A
Proxy statement
Apr 10
Annual report
10-K
FY2022, ended Dec 31
Annual report for FY2022
Revenue $0
Net loss $42.2M
Diluted EPS -$0.59
Apr 3
Late filing notice
NT 10-K
Late filing notice
2022
Dec 16
Current report
8-K
Events of Dec 15
Shareholder vote results
Nov 21
Proxy statement
DEF 14A
Meeting Dec 15, 2022
Proxy statement
Nov 14
Quarterly report
10-Q
FY2022 Q3, ended Sep 30
Quarterly report for FY2022 Q3
Revenue $0
Net loss $8.55M
Diluted EPS -$0.11
Nov 9
Nov 9
Proxy statement
PRE 14A
Meeting Dec 15, 2022
Proxy statement
Oct 17
Current report
8-K
Regulation FD disclosure
Aug 15
Quarterly report
10-Q
FY2022 Q2, ended Jun 30
Quarterly report for FY2022 Q2
Revenue $0
Net loss $19.91M
Diluted EPS -$0.26
Aug 5
Current report
8-K
Shareholder vote results
Jul 26
Proxy statement
DEFA14A
Proxy statement
Jul 25
Proxy statement
DEFA14A
Proxy statement
Jun 30
Proxy statement
DEFA14A
Proxy statement
Jun 28
Current report
8-K
Events of Jun 27
Director or officer change, or executive pay
Jun 27
Current report
8-K
Events of Jun 24
Shareholder vote results
Jun 24
Proxy statement
DEFA14A
Proxy statement
Showing 51–100 of 197 documents